Table 2.

Demographic and clinical characteristics of the retrospective cohort.

	Exposed	Unexposed		Exposed	Unexposed
	(N = 287,614)	(N = 287,614)		(N = 287,614)	(N = 287,614)
Demographic characteristics			Possible AC-related ADEs
Age in years (mean, SD)	37.97, 18.79	37.97, 18.79	Ataxia	20,104, 6.99%	4465, 1.55%*
(median, range)	39, 5–84	39, 5–84	Constipation	2969, 1.03%	551, 0.19%*
<65 (N, %)	268,414, 93.32	268,414, 93.32	Agitation	2027, 0.70%	601, 0.21%*
⩾65 (N, %)	19,200, 6.68	19,200, 6.68	Tachycardia	1970, 0.68%	798, 0.28%*
Male (N, %)	126,376, 43.94%	126,376, 43.94%	Pupil Dilation	1436, 0.50%	978, 0.34%*
Region (N, %) South	124,538, 43.30%	76,517, 26.6%*	Fractures	1264, 0.44%	820, 0.29%*
Midwest	74,412, 25.87%	106,246, 36.94%	Syncope	979, 0.34%	302, 0.11%*
West	42,038, 14.62%	39,496, 13.73%	Hallucinations	900, 0.31%	259, 0.09%*
East	46,626, 16.21%	65,355, 22.72%	Glaucoma	745, 0.26%	1219, 0.42%*
Medicare (N, %)	10,779, 3.75%	6688, 2.33%*	Urinary retention	491, 0.17%	173, 0.06%*
Clinical characteristics			Delirium	277, 0.10%	77, 0.03%*
CDI (mean, SD)	1.39, 1.72	1.17, 1.59*	Dementia	165, 0.06%	124, 0.04%*
(median, range)	1.0, 0–16	1.0, 0–18	Irritability	19, 0.01%	13, 0.00%*
Charlson (mean, SD)	0.38, 1.01	0.32, 0.88*	Hypotension	137, 0.05%	45, 0.02%*
(median, range)	0, 0–17	0, 0–17	Fractures Colles	131, 0.05%	64, 0.02%*
Length of follow-up in days (mean, SD)	33.48, 108.8	33.48, 108.8	Xerostomia	41, 0.01%	15, 0.01%*
(median, range)	9.0, 1–4043	9.0, 1–4043	Confusion	16, 0.01%	6, 0.00%*
Sum of Outcomes (mean)	0.18	0.037*	Jerking	15, 0.01%	2, 0.00%*
(median, range)	0, 0–8	0, 0–8	Poisoning	1, 0.00%	0, 0.00%*

^*p < 0.05.

AC, Anticholinergic; ADE, adverse drug event; CDI, Chronic Disease Indicator; SD, standard deviation.